Sales of migraine drug exceed expectations at Lundbeck during third quarter
The third quarter financial results at Lundbeck were more or less as expected, though one high point was miraine drug Vyepti, where sales surpassed analysts' expectations. The company is turning up the heat on the US market as it looks to the future.
by elizabeth mønsted johansen, translated by catherine brett and daniel pedersen
There were no surprises in Lundbeck's Q3 report released on Wednesday morning. The company has more or less performed as it expected to – exceeding some targets, meeting some exactly, and narrowly missing others.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck ready to take Genmab antibody to phase II
For subscribers
